Risks associated with exposure to hazardous drugs (HDs) such as chemotherapy, have been well doc-umented over the past two decades and include miscar-riages and infertility, as well as an increased possibility of developing cancer. Nurses administering HDs are at a high risk for exposure as IV tubing is prone to drip-ping when disconnected…
Since the initial release of the International Society of Oncology Pharmacy Practitioners (ISOPP) Standards for the Safe Handling of Cytotoxic Drugs in 2007, much has evolved in oncology pharmacy. Safe handling practices have been refined and new hazardous agents have been discovered and developed for treatment to pose new challenges for workers caring for their patients…
On 9 December 2021, Parliament’s Special Committee on Beating Cancer adopted its final proposals on how to strengthen the EU’s role in the fight against cancer. They include the following…
Press Release - 16 December 2021 The Stop Cancer at Work Campaign today welcomes the provisional political agreement by the European Parliament and European Council to include for the first time greater protection and reference to reprotoxic substances and...
Background The toxic effects of antineoplastic drugs used for cancer treatment have been well known since their introduction in the 1940s. However, beyond the patient safety concerns arising from the necessary therapeutic use of these drugs, the occupational risks to...
The Council presidency and the European Parliament have reached a provisional deal to update the carcinogens and mutagens directive, an EU law to protect workers from risks related to exposure to carcinogenic and mutagenic substances.
The trilogue process with the European Council, Parliament and Commission under the Portuguese Presidency concludes today and there has been no discussion at all on the important legislative changes to the Carcinogens and Mutagens Directive (CMD), passed by the European Parliament to protect workers from cancer and reproductive problems at work.
To reinforce protection of workers from exposure to hazardous medicinal products, including cytotoxic medicinal products: an Independent Group to European Commission made a study with different proposals.
The CytoPrevent board strongly supports the European Parliament vote to include hazardous drugs and reprotoxics in the Carcinogens and Mutagens Directive (CMD) to guaranty a safer working environment for healthcare professionals.
Today, scientific experts from several countries announce the creation of CytoPrevent, a group dedicated to make proposals and recommendations to ensure that the highest protection measures become standard for healthcare workers handling, preparing or administering hazardous drugs.